Skip to content

Study on the Biomarker Screening of Idiopathic Pulmonary Fibrosis Based on Metabonomics and the Effect of TCM Treatment Based on Syndrome Differentiation

Study on the Biomarker Screening of Idiopathic Pulmonary Fibrosis Based on Metabonomics and the Effect of TCM Treatment Based on Syndrome Differentiation

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035807
Enrollment
Unknown
Registered
2020-08-17
Start date
2020-04-24
Completion date
Unknown
Last updated
2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic pulmonary fibrosis

Interventions

Sponsors

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with stable IPF; (2) Aged 40-80 years; (3) In accord with the diagnostic criteria of TCM syndrome differentiation; (4) Not participate in any other interventional clinical trial within one month before selection; (5) Accept treatment voluntarily and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant, breastfeeding women or patients with a recent pregnancy plan; 2. Delirious, dementia, or with any mental disorder; 3. Complicated with severe cardiac insufficiency, liver and kidney diseases, bronchial asthma, chronic obstructive pulmonary disease, tumor or thoracic deformity; 4. With a condition of limb dysfunction or bedridden; 5. Known to be allergic to any component of the therapeutic drugs.

Design outcomes

Primary

MeasureTime frame
Times of acute aggravation hospitalization in one year;Lung function: DLCO%, FVC;Quality of life;

Secondary

MeasureTime frame
6-minute walk test;Dyspnea score;Clinical symptoms;

Countries

China

Contacts

Public ContactXueqing Yu

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

yxqshi@163.com+86 0371-66248624

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026